Top entities: Aflibercept, Robbins Geller Rudman & Dowd LLP, Regeneron Pharmaceuticals, United States — United States Department of Justice.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory class action

Regeneron Pharmaceuticals Faces Class Action Lawsuit

Q: When did this event occur?

First reported Jan 08, 2025; last updated Jan 26, 2025.

Q: What is the market impact?

General. The class action lawsuit against Regeneron Pharmaceuticals, coupled with the United States — United States Department of Justice complaint, has negatively impacted investor confidence in Regeneron Pharmaceuticals, leading to a significant drop in its stock price.

Analysis based on 6 articles · First reported Jan 08, 2025 · Last updated Jan 26, 2025

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against Regeneron Pharmaceuticals, coupled with the United States — United States Department of Justice complaint, has negatively impacted investor confidence in Regeneron Pharmaceuticals, leading to a significant drop in its stock price. This event highlights regulatory scrutiny in the biotechnology and pharmaceutical industries, potentially affecting other companies' reporting practices.

Biotechnology Pharmaceuticals

Event Summary

Regeneron Pharmaceuticals is facing a class action lawsuit, Radtke v. Regeneron Pharmaceuticals, Inc., alleging violations of the Securities Exchange Act of 1934. The lawsuit claims that Regeneron Pharmaceuticals made false and misleading statements by failing to disclose credit card fee payments to distributors for its product Aflibercept, which subsidized customer prices and misleadingly boosted reported Aflibercept sales. These actions allegedly violated the False Claims Act by overstating Aflibercept's Average Sales Price to federal agencies. The United States — United States Department of Justice filed a complaint against Regeneron Pharmaceuticals on April 10, 2024, based on these allegations. Furthermore, on October 31, 2024, Regeneron Pharmaceuticals announced its third-quarter 2024 financial results, showing lagging U.S. net sales for Aflibercept and Aflibercept HD, which caused its stock price to fall more than 9%. Robbins Geller Rudman & Dowd LLP is representing the investors in this class action, with a deadline for lead plaintiff appointment set for March 10, 2025.

Key Actions

100 Robbins Geller Rudman & Dowd LLP announced class action Regeneron Pharmaceuticals

95 United States — United States Department of Justice filed complaint Regeneron Pharmaceuticals

90 Regeneron Pharmaceuticals paid credit card fees

85 Regeneron Pharmaceuticals announced financial results

Entities Involved

oth

Aflibercept

Aflibercept is a primary product of Regeneron Pharmaceuticals, and its sales figures and pricing practices are central to the allegations in the class action lawsuit and the United States — United States Department of Justice complaint.

Importance 90.0 Sentiment -40.0

priv

Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is the law firm representing the purchasers and acquirers of Regeneron Pharmaceuticals securities in the class action lawsuit.

Importance 70.0 Sentiment 20.0

stock

Regeneron Pharmaceuticals

Importance 0.0 Sentiment 0.0

govactor

United States — United States Department of Justice

Importance 0.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard